Edition:
United States

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

28.78USD
17 Aug 2018
Change (% chg)

$1.56 (+5.73%)
Prev Close
$27.22
Open
$27.31
Day's High
$28.86
Day's Low
$27.04
Volume
433,278
Avg. Vol
518,862
52-wk High
$136.45
52-wk Low
$25.62

Chart for

About

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.... (more)

Overall

Beta: 1.11
Market Cap(Mil.): $1,580.31
Shares Outstanding(Mil.): 54.91
Dividend: --
Yield (%): --

Financials

  TSRO.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -9.88 -- --
ROI: -91.82 2.89 12.63
ROE: -283.75 1.65 14.82

UPDATE 2-European shares enjoy timid rebound though trade war fears linger

* France's CAC 40 underperforms as luxury stocks fall (Updates prices, adds details)

Jun 20 2018

BRIEF-Tesaro Announces Collaboration To Evaluate Zejula In Combination With Anti-PD-L1 Cancer Immunotherapy, MEK Inhibitor In Platinum-Sensitive Ovarian Cancer

* TESARO ANNOUNCES COLLABORATION TO EVALUATE ZEJULA® IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY AND MEK INHIBITOR IN PLATINUM-SENSITIVE OVARIAN CANCER

Jun 05 2018

BRIEF-Tesaro Reports Q1 Loss Per Share Of $2.98

* Q1 EARNINGS PER SHARE VIEW $-2.69 -- THOMSON REUTERS I/B/E/S

May 03 2018

BRIEF-Tesaro Announces Positive Top-Line Results From Quadra Trial Of Zejula

* TESARO ANNOUNCES POSITIVE TOP-LINE RESULTS FROM QUADRA TRIAL OF ZEJULA

Apr 24 2018

BRIEF-Tesaro Summarizes TSR-042 Clinical Data Presented At AACR

* TESARO INC - EXPECT TO COMPLETE ENROLLMENT IN MSI-H ENDOMETRIAL COHORT OF GARNET TRIAL BY END OF YEAR Source text for Eikon: Further company coverage:

Apr 16 2018

BRIEF-Tesaro And Medison Enter Into Exclusive Distribution Agreement To Commercialize Zejula In Israel

* TESARO AND MEDISON ENTER INTO EXCLUSIVE DISTRIBUTION AGREEMENT TO COMMERCIALIZE ZEJULA® IN ISRAEL

Apr 11 2018

BRIEF-Tesaro Says TOPACIO Data Demonstrates Compelling Clinical Activity Of Zejula In Patients With Type Of Ovarian Cancer

* DATA FROM TOPACIO TRIAL REPORTED AT SGO DEMONSTRATES COMPELLING CLINICAL ACTIVITY OF ZEJULA IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER

Mar 26 2018

BRIEF-Tesaro Inc Q4 Loss Per Share $3.35

* TESARO ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2017 OPERATING RESULTS

Feb 27 2018

BRIEF-Tesaro collaborates with Roche to evaluate their combination treatment for bladder cancer

* TESARO ANNOUNCES COLLABORATION TO EVALUATE COMBINATION OF ZEJULA® (NIRAPARIB) AND ANTI-PD-L1 CANCER IMMUNOTHERAPY IN METASTATIC BLADDER CANCER

Feb 26 2018

Earnings vs. Estimates